Adverse effects and safety of SGLT-2 inhibitors

Diabetes and Metabolism

Volumn 40, Issue 6, 2014, Pages S28-S34

  Halimi, S ^a   Verges B ^b  

^a UNIV GRENOBLE ALPES   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Type 2 diabetes; Adverse events; Blood pressure; Cardiovascular endpoints; Diabetes; Genital infection; SGLT 2 inhibitors

Indexed keywords

AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DRUG EFFECTS; DRUG MONITORING; HUMAN; KIDNEY; METABOLISM; MULTIDRUG RESISTANCE; URINARY EXCRETION;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MEMBRANE TRANSPORT MODULATORS; RENAL ELIMINATION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84928407115     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(14)72693-X     Document Type: Article

References (57)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statementof the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012, 35:1364-1379.
3. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:577-589.
4. Ong K.L., Cheung B.M., Wong L.Y., Wat N.M., Tan K.C., Lam K.S. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
5. Hsieh M.C., Lin K.D., Tien K.J., Tu S.T., Hsiao J.Y., Chang S.J., et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism. 2010, 59:1139-1144.
6. Oh T.J., Jung H.S., Bae J.H., Kim Y.G., Park K.S., Cho Y.M., et al. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci 2013, 28:881-887.
7. Anderson S.L., Trujillo J.M., McDermott M., Saseen J.J. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003) 2012, 52:466-471.
8. Bays H. Sodium Glucose Co-transporter Type 2 (SGLT-2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther 2013, 4:195-220.
9. Abdul-Ghani M.A., Defronzo R.A. Lowering Plasma Glucose Concentration by Inhibiting Renal Sodium-Glucose Co-Transport. J Intern Med 2014, Apr 1. doi: 10.1111/joim.12244. [Epub ahead of print] PubMed PMID: 24690096.
10. Perkins B.A., Cherney D.Z., Partridge H., Soleymanlou N., Tschirhart H., Zinman B., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014, 37:1480-1483.
11. Hiatt W.R., Kaul S., Smith R.J. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med 2013, 369:1285-1287.
12. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf.
13. Monami M., Dicembrini I., Mannucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014, 51:91-101.
14. Monami M., Dicembrini I., Martelli D., Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011, 27:57-64.
15. Alves C., Batel-Marques F., Macedo A.F. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012, 98:271-284.
16. FDA., 2013 Jan 23. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf.
17. FDA., 2013 Dec. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf.
18. Janssen Pharmaceuticals Inc. InvokanaTM (canagliflozin) tablets, for oral use: US prescribing information. Available from:. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf.
19. FDA. http://www.drugs.com/newdrugs/fda-approves-jardiance-empagliflozin-%20type-2-diabetes-4064.html.
20. Ly J.P., Onay T., Sison K., Sivaskandarajah G., Sabbisetti V., Li L., et al. The Sweet Pee model for SGLT-2 mutation. J Am Soc Nephrol 2011, 22:113-123.
21. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
22. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. VADT Investigators.
23. Lundkvist J., Berne C., Bolinder B., Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005, 6:197-202..
24. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013, 15:432-440.
25. Bhatia J., Gamad N., Bharti S., Arya D.S. Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J Diabetes 2014, 5:399-406.
26. Kaushal S., Singh H., Thangaraju P., Singh J., Canagliflozin: A Novel SGLT-2 Inhibitor for Type 2 Diabetes Mellitus. N Am J Med Sci 2014, 6:107-113.
27. Cefalu W.T., Leiter L.A., Yoon K.H., Arias P., Niskanen L., Xie J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
28. Rosenstock J., Seman L.J., Jelaska A., Hantel S., Pinnetti S., Hach T., et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013, 15:1154-1160.
29. Johnsson K.M., Ptaszynska A., Schmitz B., Sugg J., Parikh S.J., List J.F. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013, 27:479-484.
30. Nyirjesy P., Sobel J.D., Fung A., Mayer C., Capuano G., Ways K., et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014, 30:1109-1119.
31. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 013;27:473-8.
32. Rosenstock J., Vico M., Wei L., Salsali A., List J.F. Effects of dapagliflozin, an SGLT-2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012, 35:1473-1478.
33. Kovacs C.S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2013, On behalf of the EMPA-REG PIO™ trial investigators, Aug 1. doi:10.1111/dom. 12188. [Epub ahead of print].
34. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 2013, 36:2508-2515. [Erratum in: Diabetes Care 36: 4172].
35. Rosenstock J., Aggarwal N., Polidori D., Zhao Y., Arbit D., Usiskin K., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 35:1232-1238. Canagliflozin DIA 2001 Study Group.
36. List J.F., Woo V., Morales E., Tang W., Fiedorek F.T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.
37. Nauck M., Prato S.D., Rohwedder K., Elze M., Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-weekresults of a double-blind, randomised controlled trial. Diabetologia 2010, 53:S1-S556.
38. Oliva R.V., Bakris G.L. Blood pressure effects of sodium-glucose co-transport 2 (SGLT-2) inhibitors. J Am Soc Hypertens 2014, 8:330-339.
39. Yale J.F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
40. Panchapakesan U., Pegg K., Gross S., Komala M.G., Mudaliar H., Forbes J., et al. Effects of SGLT-2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy?. PLoS One 2013, 8:e54442.
41. Stanton R.C. Sodium glucose transport 2 (SGLT-2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT-2 inhibitors in diabetic kidney disease?. Circulation 2014, 129:542-544.
42. Lamos E.M., Younk L.M., Davis S.N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013, 9:763-775.
43. Dziuba J., Alperin P., Racketa J., Iloeje U., Goswami D., Hardy E., et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014, 16:628-635.
44. Leiter L.A., Cefalu W.T., de Bruin T.W., Gause-Nilsson I., Sugg J., Parikh S.J. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014, 62:1252-1262.
45. Neal B., Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Stein P., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebocontrolled trial. Am Heart J 2013, 166:217-223.
46. Ridderstråle M., Svaerd R., Zeller C., Kim G., Woerle H.J., Broedl U.C. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT-2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013 5, 12:129. EMPA-REG H2H-SU trial investigators.
47. DECLARE Trial. Dapaglifozin. http://clinicaltrials.gov/show/NCT01730534.
48. Kasichayanula S., Chang M., Liu X., Shyu W.C., Griffen S.C., LaCreta F.P., et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 2012, 29:163-177.
49. Food and Drug Administration. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10mg. In: Products DoMae (ed). Silver Spring: Food and Drug Administration 2011.
50. Chino Y., Samukawa Y., Sakai S., Nakai Y., Yamaguchi J.I., Nakanishi T., et al. SGLT-2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014, Jul 7. doi: 10.1002/bdd.1909 [Epub ahead of print].
51. John Senior and Leonard Seeff to Mary Parks. Possible hepatic adverse effects of canagliflozin. 28 November 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000OtherR.pdf.
52. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Investigation into GLP-1 based diabetes therapies concluded. No new concerns for GLP-1 therapies identified on the basis of available evidence. 26 July 2013. http://www.ema.europa.eu/ema/index.
53. FDA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378079.
54. Bolinder J., Ljunggren O., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97:1020-1031.
55. Ljunggren Ö., Bolinder J., Johansson L., Wilding J., Langkilde A.M., Sjöström C.D., et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012, 14:990-999.
56. FDA., 2013 Jan 23. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM336236.pdf.
57. Monami M., Nardini C., Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014, 16:457-466.